Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Fajac

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
ERJ Open Research|March 5, 2025
Efficacy and safety of CFTR modulators in patients with interstitial lung disease caused by ABCA3 transporter deficiencyMathilde Le Brun, Nadia Nathan, Camille Louvrier, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 28, 2019
Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosisDiana Bilton, Tacjana Pressler, Isabelle Fajac, et al.
Thorax|June 5, 2010
Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosisIsabelle Sermet-Gaudelus, Emmanuelle Girodon, Delphine Roussel, et al.
The Lancet. Respiratory Medicine|September 12, 2023
Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapyKatherine B Hisert, Susan E Birket, John Paul Clancy, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 20, 2021
Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosisJ Stuart Elborn, Michael W Konstan, Jennifer L Taylor-Cousar, et al.
The European Respiratory Journal|July 1, 2022
Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat testThao Nguyen-Khoa, Aurélie Hatton, David Drummond, et al.
American Journal of Respiratory and Critical Care Medicine|June 12, 2010
Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transportIsabelle Sermet-Gaudelus, Emanuelle Girodon, Dorota Sands, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 4, 2025
Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatmentEdith T Zemanick, Bonnie Ramsey, Dorota Sands, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 28, 2021
Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled studyLaurent Meijer, Geneviève Hery-Arnaud, Cyril Leven, et al.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis and Rare CFTR Variants: In Vitro Translation to a Phase 3, Double-Blind, Randomized, Placebo-controlled Trial and Real-World StudyCarlo Castellani, Pedro Mondejar-Lopez, Fredrick Van Goor, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
ERJ Open Research|March 5, 2025
Efficacy and safety of CFTR modulators in patients with interstitial lung disease caused by ABCA3 transporter deficiencyMathilde Le Brun, Nadia Nathan, Camille Louvrier, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 28, 2019
Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosisDiana Bilton, Tacjana Pressler, Isabelle Fajac, et al.
Thorax|June 5, 2010
Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosisIsabelle Sermet-Gaudelus, Emmanuelle Girodon, Delphine Roussel, et al.
The Lancet. Respiratory Medicine|September 12, 2023
Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapyKatherine B Hisert, Susan E Birket, John Paul Clancy, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 20, 2021
Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosisJ Stuart Elborn, Michael W Konstan, Jennifer L Taylor-Cousar, et al.
The European Respiratory Journal|July 1, 2022
Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat testThao Nguyen-Khoa, Aurélie Hatton, David Drummond, et al.
American Journal of Respiratory and Critical Care Medicine|June 12, 2010
Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transportIsabelle Sermet-Gaudelus, Emanuelle Girodon, Dorota Sands, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 4, 2025
Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatmentEdith T Zemanick, Bonnie Ramsey, Dorota Sands, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 28, 2021
Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled studyLaurent Meijer, Geneviève Hery-Arnaud, Cyril Leven, et al.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis and Rare CFTR Variants: In Vitro Translation to a Phase 3, Double-Blind, Randomized, Placebo-controlled Trial and Real-World StudyCarlo Castellani, Pedro Mondejar-Lopez, Fredrick Van Goor, et al.
Pageof 8